This course has expired. View available courses.
Rheumatology, Gastroenterology , Dermatology
Biosimilars in Australia: biosimilar infliximab – opportunities in management of chronic inflammatory disease – Certificate of Completion
DURATION
PROFESSION
Specialist
# OF CREDITS
2
ACCREDITATION
Certificate of Completion
EXPIRY DATE
2017-12-12
Learning objectives
After completing this program, participants will be better able to:
- Recognise what biosimilars are and describe differences in the Australian regulatory approval process for biosimilars and generics.
- Describe current issues around biosimilars: extrapolation of indications, interchangeability, naming convention.
- Appraise the impact of biosimilar infliximab on the management of inflammatory bowel disease, rheumatological disease and psoriasis.
- Outline issues to consider including relevant safety and efficacy data and prescribing requirements when selecting biosimilar infliximab for patients with inflammatory bowel disease, rheumatological disease and psoriasis.
- Describe the potential impact of switching from originator infliximab to biosimilar or one biosimilar infliximab to other biosimilar infliximab products.